文献速递母胎医学

产前西罗莫司对胎儿心脏横纹肌瘤及脑结节的影响

Impact of prenatal sirolimus on cardiac rhabdomyomas and brain tubers.
PubMed 文献 · Ultrasound Obstet Gynecol · 2026-02-12

这项单中心回顾性队列研究纳入27例疑似胎儿心脏横纹肌瘤妊娠,其中7例接受产前西罗莫司治疗。研究评估肿瘤大小、心脏并发症及脑结节大小的变化。结果显示早期且持续使用产前西罗莫司与心脏横纹肌瘤缩小或心脏并发症缓解相关,停药后出现反弹生长,对脑结节的影响因样本量过小无法确定。

要点

  • 未治疗时心脏横纹肌瘤在孕20+0至27+6周增长较快,28周后增速减慢。
  • 产前西罗莫司治疗超过7天与肿瘤缩小或流出道梗阻缓解相关。
  • 产前西罗莫司停药后可出现肿瘤反弹生长。

核心结论

  • 早期且持续的产前西罗莫司治疗与心脏横纹肌瘤缩小和/或心脏并发症缓解相关。
  • 停止产前西罗莫司治疗后观察到肿瘤反弹生长。
  • 产前西罗莫司治疗对脑结节似乎无影响,但样本量过小无法得出明确结论。

研究设计与样本

  • 单中心回顾性队列研究,纳入2013年4月至2024年5月转诊的可疑胎儿心脏横纹肌瘤妊娠。
  • 共纳入27例妊娠,其中7例接受产前西罗莫司治疗。
  • 通过回顾系列超声和超声心动图报告获取肿瘤特征及心脏并发症信息。
  • 产前和产后脑部磁共振成像由两名对产前西罗莫司治疗不知情的观察者审阅。

主要发现

  • 治疗开始前,未治疗组与产前西罗莫司组最大心脏肿瘤直径相似(平均15.2 mm对14.3 mm;P = 0.72)。
  • 未治疗时,横纹肌瘤从孕20+0至27+6周快速生长(平均2.58 mm/周),28周后增速减慢(平均0.44 mm/周)。
  • 4例出现胎儿水肿,发生时平均肿瘤直径为31.7 ± 6.2 mm,平均肿瘤/股骨长比值为0.68 ± 0.15,平均生长速率为4.3 ± 1.7 mm/周。
  • 产前西罗莫司治疗超过7天的3例中,出现肿瘤消退和/或流出道梗阻缓解,肿瘤/股骨长比值下降;2例产前停药后出现反弹生长。
  • 产前西罗莫司治疗7天或以下的4例未影响肿瘤大小,也未缓解已有心脏并发症。

关键数值与推荐

  • 未治疗时心脏横纹肌瘤在孕20+0至27+6周平均每周增长2.58 mm,28周后平均每周增长0.44 mm。
  • 产前磁共振成像中,皮质下结节和室管膜下结节各在67%的病例中检出,室管膜下巨细胞星形细胞瘤在58%的病例中检出。
  • 产后磁共振成像中,脑结节在92%的病例中检出。

临床怎么用

  • 对于胎儿心脏横纹肌瘤导致流出道梗阻或快速增长的病例,可考虑早期启动产前西罗莫司治疗。
  • 产前西罗莫司治疗应持续进行,停药可能导致肿瘤反弹生长。
  • 产前西罗莫司对脑结节的作用尚不明确,需结合后续研究判断。

局限性

  • 回顾性单中心设计,样本量较小,尤其是接受产前西罗莫司治疗的病例仅7例。
  • 脑结节评估部分病例同时有产前和产后磁共振成像者数量很少。
  • 脑结节结局因样本量过小无法得出明确结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To document the natural progression of fetal cardiac rhabdomyomas and evaluate the impact of prenatal sirolimus (PNS) on tumor size, cardiac complications and brain-tuber size. METHODS: This was a single-center retrospective cohort study of pregnancies with suspected fetal cardiac rhabdomyoma referred to our center from April 2013 to May 2024. Serial ultrasound and echocardiography reports were reviewed to obtain tumor characteristics, such as diameter and location, and cardiac complications, including inflow or outflow obstruction, arrhythmia and hydrops. The tumor-to-femur length (TFL) ratio was calculated to correct for fetal growth. Prenatal neurosonography reports were collected from clinical records. Pre- and postnatal brain magnetic resonance imaging (MRI) scans were reviewed by two observers who were blinded to PNS treatment. Brain-lesion severity was assessed based on the presence of subependymal nodules, the EPISTOP score, the maximum diameter of the largest subcortical tuber, the maximum diameter of the largest subependymal giant cell astrocytoma (SEGA) and the diameter of the largest lateral ventricle. Prenatal or postnatal genetic testing results were documented when available. RESULTS: Twenty-seven pregnancies were included in the study, seven of which received PNS. Prior to initiation of treatment, the diameter of the largest cardiac tumor at diagnosis was similar between the non-PNS and PNS groups (mean, 15.2 mm vs 14.3 mm; P = 0.72), with the left ventricle the most frequently affected location. Without treatment, rhabdomyomas grew rapidly from 20 + 0 to 27 + 6 weeks' gestation (mean, 2.58 mm/week) but growth slowed after 28 weeks (mean, 0.44 mm/week). Hydrops was reported in four cases and occurred at a mean tumor diameter of 31.7 ± 6.2 mm, mean TFL ratio of 0.68 ± 0.15 and at a mean growth rate of 4.3 ± 1.7 mm/week. In the seven women treated with PNS, treatment for > 7 days (n = 3) resulted in tumor regression and/or resolution of outflow obstruction, and a reduction in TFL ratio; however, prenatal cessation of treatment resulted in rebound growth (n = 2). Treatment for ≤ 7 days (n = 4) did not impact tumor size or resolve existing cardiac complications. Among the 12 cases that underwent prenatal MRI, the median EPISTOP score was 7 (interquartile range (IQR), 1-15) and the median largest lateral ventricle diameter was 8.9 (IQR, 7.0-9.7) mm; subcortical tubers and subependymal nodules were each identified in 67% of cases, and SEGAs were identified in 58%. Among the 13 cases that underwent postnatal MRI, the median EPISTOP score was 14 (IQR, 3-16) and the median largest lateral ventricle diameter was 7 (IQR, 7-8) mm; brain tubers were identified in 92% of cases. In cases with both pre- and postnatal MRI findings who received PNS for > 7 days (n = 3), on postnatal MRI compared with prenatal MRI, one patient showed no change in findings, one demonstrated a mild increase in the largest subcortical tuber diameter and one had no detectable brain tubers. CONCLUSIONS: Early and sustained PNS treatment was associated with reduced cardiac rhabdomyoma size and/or resolution of cardiac complications. Rebound tumor growth was observed after discontinuation of treatment. Brain tubers appeared unchanged with PNS treatment, although the sample size was too small to draw a definitive conclusion. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Vergote, Van der Veeken, Chitayat, et al. Impact of prenatal sirolimus on cardiac rhabdomyomas and brain tubers. Ultrasound Obstet Gynecol. 2026. PMID: 41674351. doi:10.1002/uog.70185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。